TREA

90302471 - TIZUREST

Follow

Information

  • Trademark
  • 90302471
  • Serial Number
    90302471
  • Filing Date
    November 06, 2020
    3 years ago
  • Transaction Date
    July 25, 2024
    2 months ago
  • Status Date
    July 22, 2024
    2 months ago
  • Published for Opposition Date
    December 13, 2022
    a year ago
  • Location Date
    February 07, 2023
    a year ago
  • Status Code
    732
  • Current Location
    INTENT TO USE SECTION
    Employee Name
    POWERS, ALEXANDER L
  • Attorney Docket Number
    720626007000
    Attorney Name
    Muzamil Huq
    Law Office Assigned Location Code
    L10
  • Owners
Information
Mark Drawing Code
4
Mark Identification
TIZUREST
Case File Statements
  • GS0051: Chemical pharmaceutical preparations in the nature of chemical preparations for pharmaceutical purposes for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; human medicines for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; biochemical drugs for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; pharmaceutical preparations for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medicinal capsules for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical chemical preparations in the nature of chemical preparations for medical purposes for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical biological preparations for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical ointments, namely, medicated ointments for treating or preventing inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical drugs for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical diagnostic preparations
Case File Event Statements
  • 11/10/2020 - 3 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 1/6/2021 - 3 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 4/14/2021 - 3 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 4/16/2021 - 3 years ago
    5 - PRIORITY ACTION E-MAILED Type: GPRA
  • 4/16/2021 - 3 years ago
    4 - PRIORITY ACTION WRITTEN Type: CPRA
  • 4/16/2021 - 3 years ago
    6 - NOTIFICATION OF PRIORITY ACTION E-MAILED Type: GPRN
  • 6/16/2021 - 3 years ago
    7 - AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Type: ASGN
  • 9/30/2021 - 2 years ago
    8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 9/30/2021 - 2 years ago
    9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 10/1/2021 - 2 years ago
    10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 4/20/2022 - 2 years ago
    15 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI
  • 10/4/2021 - 2 years ago
    11 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 10/4/2021 - 2 years ago
    12 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 10/4/2021 - 2 years ago
    13 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3
  • 4/20/2022 - 2 years ago
    14 - SUSPENSION INQUIRY WRITTEN Type: CNSI
  • 4/20/2022 - 2 years ago
    16 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2
  • 9/26/2022 - 2 years ago
    18 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI
  • 11/8/2022 - a year ago
    19 - ASSIGNED TO LIE Type: ALIE
  • 5/31/2022 - 2 years ago
    17 - ASSIGNED TO EXAMINER Type: DOCK
  • 11/10/2022 - a year ago
    20 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 11/10/2022 - a year ago
    21 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 11/10/2022 - a year ago
    22 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 11/23/2022 - a year ago
    23 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 12/13/2022 - a year ago
    25 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 12/13/2022 - a year ago
    24 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 8/7/2023 - a year ago
    29 - SOU EXTENSION 1 GRANTED Type: EX1G
  • 2/7/2023 - a year ago
    26 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 8/7/2023 - a year ago
    27 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 8/7/2023 - a year ago
    28 - SOU EXTENSION 1 FILED Type: EXT1
  • 8/9/2023 - a year ago
    30 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 1/22/2024 - 8 months ago
    35 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 1/3/2024 - 8 months ago
    32 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 1/3/2024 - 8 months ago
    31 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 1/3/2024 - 8 months ago
    33 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 1/22/2024 - 8 months ago
    36 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 1/22/2024 - 8 months ago
    34 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR
  • 2/5/2024 - 7 months ago
    38 - SOU EXTENSION 2 FILED Type: EXT2
  • 2/5/2024 - 7 months ago
    39 - SOU EXTENSION 2 GRANTED Type: EX2G
  • 7/23/2024 - 2 months ago
    43 - SOU EXTENSION 3 GRANTED Type: EX3G
  • 7/23/2024 - 2 months ago
    42 - SOU EXTENSION 3 FILED Type: EXT3
  • 7/24/2024 - 2 months ago
    44 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 7/22/2024 - 2 months ago
    41 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 2/5/2024 - 7 months ago
    37 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 2/7/2024 - 7 months ago
    40 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA